Willeke and Bas went to the AD/PD2024 conference in Lisbon starting on March 5th. This conference aims to share novel insights into the disease mechanisms and therapeutic innovations in Alzheimer’s Disease and Parkinson’s Disease. The first day was kicked off with a fireside chat with Michael J. Fox, who shared his experiences on living with […]
On Monday 29th January the CureQ consortium gathered for the first annual general assembly. The day kicked off with an overview of our progress over the year, sparkling lively discussions among the attendants. The morning session culminated with a captivating workshop on effective communication, which had us all stepping into each other’s shoes while discovering […]
On September 21st, Elena Daoutsali defended her thesis: 3D modeling and RNA-based therapeutics for Dutch-type Cerebral Amyloid Angiopathy. She did very well! Afterwards, her achievements were celebrated with her family and friends, where some travelled all the way from Greece. Elena has been awarded a Dementia Fellowship from ZonMw and will be starting her new […]
In the weekend of 24 June 2023 we went with (almost) all lab members for a NeuroD lab family weekend. Also partners and children joined, so we were with a big group. We rented a house in Ulvenhout and had nice food, games and quality time. On Saturday we went to a farm to do […]
Good news! Our research paper titled “Amyloid beta (Aβ) accumulations and enhanced forebrain neuronal development and neuronal network formation in cerebral organoids of Dutch-type Cerebral Amyloid Angiopathy patients” was accepted for publication in Frontiers in Aging Neuroscience. Willeke ordered a cake with one of the figures from the paper on it to celebrate with first […]
Great news! The CureQ consortium has been granted by the NWO (Dutch Research Council) and started this month. The CureQ program focusses on a distinct group of dominantly inherited neurodegenerative disorders caused by a CAG repeat expansion within the relevant genes, including Huntington’s disease (HD) and various spinocerebellar ataxias (SCA). Over 5.5 million euro will […]
Ronald Buijsen is this year’s recipient of the Gewirtz Award for postdoctoral researchers and Young Industrial Professionals of the Oligonucleotide Therapeutics Society (OTS). He received the award for his contributions in the field of oligonucleotide therapeutics. The award is given in honor of Professor Alan Gewirtz, one of the founders of the oligonucleotide therapy field […]
On Monday 3 October, the kick-off of our CureQ consortium was held: an introduction of all those involved who will work together over the next 5 years on predicting, delaying and curing the hereditary polyglutamine brain diseases Huntington, SCA1 and SCA3 (www.cureQ.nl). Researchers and neurologists from various Dutch universities, various HBO courses, ethicists, biotechnology companies, […]
The first participant of the SCA7 study reported yesterday at our Radboudumc Expertise Center for Rare and Hereditary Movement Disorders. With this, we have officially started the research into the natural course and possible biomarkers in this disease! This is an important step towards the ultimate long-term goal: slow down, stop or prevent the disease! […]
Elena Daoutsali and Ronald Buijsen from the NeuroD research group were awarded the Sargenti Research Grant, organized by the Neuroscience Research Theme. The grant was for the field of neurodegenerative diseases and made possible through a donation from the legacy of mr. Sargenti to the Leiden University Fund. Together with the group of Saskia Lesnik […]